Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.15
SHPG's Cash to Debt is ranked higher than
50% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. SHPG: 0.15 )
SHPG' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: 0.15

Equity to Asset 0.54
SHPG's Equity to Asset is ranked higher than
65% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. SHPG: 0.54 )
SHPG' s 10-Year Equity to Asset Range
Min: 0.25   Max: 0.85
Current: 0.54

0.25
0.85
Interest Coverage 45.50
SHPG's Interest Coverage is ranked higher than
57% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SHPG: 45.50 )
SHPG' s 10-Year Interest Coverage Range
Min: 2.96   Max: 45.5
Current: 45.5

2.96
45.5
F-Score: 4
Z-Score: 7.38
M-Score: -2.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 35.81
SHPG's Operating margin (%) is ranked higher than
96% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. SHPG: 35.81 )
SHPG' s 10-Year Operating margin (%) Range
Min: -56.61   Max: 35.13
Current: 35.81

-56.61
35.13
Net-margin (%) 20.38
SHPG's Net-margin (%) is ranked higher than
93% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. SHPG: 20.38 )
SHPG' s 10-Year Net-margin (%) Range
Min: -59.59   Max: 24.16
Current: 20.38

-59.59
24.16
ROE (%) 18.28
SHPG's ROE (%) is ranked higher than
94% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. SHPG: 18.28 )
SHPG' s 10-Year ROE (%) Range
Min: -118.32   Max: 27.16
Current: 18.28

-118.32
27.16
ROA (%) 9.86
SHPG's ROA (%) is ranked higher than
93% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. SHPG: 9.86 )
SHPG' s 10-Year ROA (%) Range
Min: -33.53   Max: 13.56
Current: 9.86

-33.53
13.56
ROC (Joel Greenblatt) (%) 150.56
SHPG's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. SHPG: 150.56 )
SHPG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -374.15   Max: 189.47
Current: 150.56

-374.15
189.47
Revenue Growth (%) 10.80
SHPG's Revenue Growth (%) is ranked higher than
85% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. SHPG: 10.80 )
SHPG' s 10-Year Revenue Growth (%) Range
Min: -1   Max: 54.2
Current: 10.8

-1
54.2
EBITDA Growth (%) 22.80
SHPG's EBITDA Growth (%) is ranked higher than
92% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. SHPG: 22.80 )
SHPG' s 10-Year EBITDA Growth (%) Range
Min: -0.7   Max: 66.3
Current: 22.8

-0.7
66.3
EPS Growth (%) 32.00
SHPG's EPS Growth (%) is ranked higher than
94% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. SHPG: 32.00 )
SHPG' s 10-Year EPS Growth (%) Range
Min: -5.6   Max: 61.5
Current: 32

-5.6
61.5
» SHPG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

SHPG Guru Trades in Q3 2013

Andreas Halvorsen 849,800 sh (+22.64%)
Ken Fisher 2,405 sh (unchged)
John Paulson 2,843,500 sh (unchged)
Murray Stahl 6,000 sh (unchged)
Pioneer Investments 120,183 sh (-0.53%)
Jim Simons 589,000 sh (-14.65%)
Steven Cohen 121,440 sh (-35.68%)
» More
Q4 2013

SHPG Guru Trades in Q4 2013

Andreas Halvorsen 1,223,005 sh (+43.92%)
Jim Simons 619,212 sh (+5.13%)
Murray Stahl 6,000 sh (unchged)
Ken Fisher 2,340 sh (-2.7%)
Steven Cohen 115,702 sh (-4.72%)
John Paulson 2,529,854 sh (-11.03%)
Pioneer Investments 85,846 sh (-28.57%)
» More
Q1 2014

SHPG Guru Trades in Q1 2014

Ken Fisher 2,447 sh (+4.57%)
John Paulson 2,529,854 sh (unchged)
Murray Stahl 6,000 sh (unchged)
Jim Simons 561,700 sh (-9.29%)
Pioneer Investments 61,509 sh (-28.35%)
Steven Cohen 66,000 sh (-42.96%)
Andreas Halvorsen 399,840 sh (-67.31%)
» More
Q2 2014

SHPG Guru Trades in Q2 2014

Eric Mindich 251,000 sh (New)
Louis Moore Bacon 5,000 sh (New)
Ken Fisher 4,677 sh (+91.13%)
John Paulson 3,366,539 sh (+33.07%)
Jim Simons 675,575 sh (+20.27%)
Murray Stahl 6,000 sh (unchged)
Andreas Halvorsen Sold Out
Pioneer Investments 36,744 sh (-40.26%)
» More
» Details

Insider Trades

Latest Guru Trades with SHPG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2014-06-30 Add 33.07%0.84%$142.83 - $234.98 $ 257.549%3366539
John Paulson 2013-12-31 Reduce -11.03%0.24%$113.87 - $140.87 $ 257.596%2529854
John Paulson 2013-06-30 Add 107.43%0.98%$86.59 - $99.85 $ 257.5175%2843500
Mario Gabelli 2013-03-31 Sold Out 0.003%$89.83 - $101.63 $ 257.5169%0
John Paulson 2012-09-30 New Buy0.99%$84.65 - $95.05 $ 257.5186%1370800
John Hussman 2012-09-30 Sold Out 0.3%$84.65 - $95.05 $ 257.5186%0
John Keeley 2012-03-31 Sold Out 0.0046%$97.29 - $108.2 $ 257.5167%0
Mario Gabelli 2012-03-31 New Buy$97.29 - $108.2 $ 257.5167%5460
John Keeley 2011-12-31 New Buy$88.04 - $103.9 $ 257.5167%2105
John Keeley 2011-09-30 Sold Out 0.0035%$87.43 - $104 $ 257.5168%0
John Keeley 2011-06-30 Reduce -36.62%$87.92 - $96.32 $ 257.5181%2285
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 47.00
SHPG's P/E(ttm) is ranked higher than
90% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPG: 47.00 )
SHPG' s 10-Year P/E(ttm) Range
Min: 13.99   Max: 74
Current: 47

13.99
74
P/B 8.67
SHPG's P/B is ranked higher than
67% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. SHPG: 8.67 )
SHPG' s 10-Year P/B Range
Min: 2   Max: 14.39
Current: 8.67

2
14.39
P/S 9.67
SHPG's P/S is ranked higher than
80% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. SHPG: 9.67 )
SHPG' s 10-Year P/S Range
Min: 2.23   Max: 9.7
Current: 9.67

2.23
9.7
PFCF 25.76
SHPG's PFCF is ranked higher than
95% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPG: 25.76 )
SHPG' s 10-Year PFCF Range
Min: 9.79   Max: 42.14
Current: 25.76

9.79
42.14
EV-to-EBIT 24.40
SHPG's EV-to-EBIT is ranked higher than
92% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPG: 24.40 )
SHPG' s 10-Year EV-to-EBIT Range
Min: 6.9   Max: 34.4
Current: 24.4

6.9
34.4
PEG 2.75
SHPG's PEG is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPG: 2.75 )
SHPG' s 10-Year PEG Range
Min: 1.06   Max: 3.24
Current: 2.75

1.06
3.24
Shiller P/E 64.99
SHPG's Shiller P/E is ranked higher than
94% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPG: 64.99 )
SHPG' s 10-Year Shiller P/E Range
Min: 30.76   Max: 143.7
Current: 64.99

30.76
143.7
Current Ratio 1.18
SHPG's Current Ratio is ranked higher than
52% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. SHPG: 1.18 )
SHPG' s 10-Year Current Ratio Range
Min: 0.67   Max: 7.43
Current: 1.18

0.67
7.43
Quick Ratio 0.91
SHPG's Quick Ratio is ranked higher than
52% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. SHPG: 0.91 )
SHPG' s 10-Year Quick Ratio Range
Min: 0.53   Max: 7.07
Current: 0.91

0.53
7.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.20
SHPG's Dividend Yield is ranked lower than
88% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. SHPG: 0.20 )
SHPG' s 10-Year Dividend Yield Range
Min: 0.19   Max: 0.68
Current: 0.2

0.19
0.68
Dividend Payout 0.07
SHPG's Dividend Payout is ranked higher than
100% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPG: 0.07 )
SHPG' s 10-Year Dividend Payout Range
Min: 0.06   Max: 1.23
Current: 0.07

0.06
1.23
Dividend growth (3y) 15.70
SHPG's Dividend growth (3y) is ranked higher than
89% of the 79 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. SHPG: 15.70 )
SHPG' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 57.7
Current: 15.7

0
57.7
Yield on cost (5-Year) 0.38
SHPG's Yield on cost (5-Year) is ranked lower than
77% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. SHPG: 0.38 )
SHPG' s 10-Year Yield on cost (5-Year) Range
Min: 0.36   Max: 1.28
Current: 0.38

0.36
1.28

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.62
SHPG's Price/DCF (Projected) is ranked higher than
95% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPG: 2.62 )
SHPG' s 10-Year Price/DCF (Projected) Range
Min: 1.01   Max: 2.65
Current: 2.62

1.01
2.65
Price/Median PS Value 2.31
SHPG's Price/Median PS Value is ranked higher than
71% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. SHPG: 2.31 )
SHPG' s 10-Year Price/Median PS Value Range
Min: 0.57   Max: 2.5
Current: 2.31

0.57
2.5
Price/Peter Lynch Fair Value 3.24
SHPG's Price/Peter Lynch Fair Value is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPG: 3.24 )
SHPG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.72   Max: 2.92
Current: 3.24

0.72
2.92
Earnings Yield (Greenblatt) 4.10
SHPG's Earnings Yield (Greenblatt) is ranked higher than
73% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. SHPG: 4.10 )
SHPG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.9   Max: 14.5
Current: 4.1

2.9
14.5
Forward Rate of Return (Yacktman) 15.66
SHPG's Forward Rate of Return (Yacktman) is ranked higher than
95% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. SHPG: 15.66 )
SHPG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.3   Max: 22.6
Current: 15.66

1.3
22.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SHP.UK, SHPGF.USA, S7E.Germany, SP2.Germany
Shire PLC is a biopharmaceutical company that focuses on meeting the needs of the specialist physician. The Company develops and provides healthcare in the areas of Behavioral Health and Gastro Intestinal conditions; Rare Genetic Diseases; and Regenerative Medicine. The Company operates in three distinct business units; Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine. Specialty Pharmaceuticals focus on small-molecule medications within the therapeutic areas of Behavioral Health and Gastro Intestinal disease, among others. Human Genetic Therapies is solely focused on researching, developing and marketing novel products and services that profoundly enhance the quality of life of patients suffering from rare genetic diseases. Regenerative Medicine provides regenerative medicine solutions for people with lifealtering conditions. The company operates in Ireland, United Kingdom, North America and Rest of World.
» More Articles for NAS:SHPG

Headlines

Articles On GuruFocus.com
Invesco European Growth Fund Comments on Shire PLC Jul 29 2014 
Invesco European Growth Fund Second Quarter 2014 Commentary Jul 29 2014 
Weekly 52-Week Highs Highlight: SHPG, ILMN, UA, WDAY Feb 23 2014 
Paulson Says Bet Against Europe to Blame for Down Year, Slashed EU Holdings in Q3 Dec 06 2012 
John Paulson’s 4 Stocks Trading at 52-Week Lows Nov 28 2012 
Top 4 International Stocks at 52-Week Low Prices Oct 31 2012 


More From Other Websites
8:01 am Shire plc announces FDA acceptance for filing with priority review of sNDA for Vyvanse... Sep 15 2014
Shire Announces FDA Acceptance for Filing with Priority Review of Supplemental New Drug Application... Sep 15 2014
2 Senators Introduce New Anti-Inversion Bill Sep 10 2014
Schumer sees deal on inversions in lame-duck session Sep 10 2014
[$$] Elliott Drops 0.8% in August For Rare Loss Sep 10 2014
3 Stocks Boosting The Drugs Industry Higher Sep 09 2014
[video] Inversion crackdown all talk, no action? Sep 08 2014
Treasury Secretary's Upcoming Inversion Talk to Widen Spreads Sep 05 2014
Will AbbVie's $805 Million Agreement for Duvelisib Pay Off? Sep 04 2014
10 Stocks Billionaire John Paulson Loves in 2014 Sep 04 2014
SHIRE PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 02 2014
[$$] Medtronic, AbbVie to Reimburse for Inversion-Triggered Taxes Aug 29 2014
Protalix/Pfizer's Elelyso Approved in Pediatric Patients Aug 29 2014
The Zacks Analyst Blog Highlights: RadioShack, Amicus Therapeutics, Sanofi, Shire and Gilead... Aug 28 2014
3 Drugs Stocks Dragging The Industry Down Aug 27 2014
[$$] Roche to Acquire InterMune for $8.3 Billion Aug 25 2014
IRS, Eh? Tim Hortons Deal Could Lower Burger King's Tax Bill Aug 25 2014
Burger King may buy Canada’s Tim Hortons to cut its taxes Aug 24 2014
Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day Aug 22 2014
Amicus Therapeutics (FOLD) Soars on Fabry Drug Trial Results Aug 21 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK